Lorlatinib vs crizotinib as first-line treatment for advanced <i>ALK</i> + non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
Journal of Clinical Oncology · 2026-05-28
Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison
Journal of Comparative Effectiveness Research · 2025-12-15 · 1 citations
Supplementary Figure 1 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
2025-12-11
Supplementary Table 1 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
2025-12-11
Supplementary Table 2 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
2025-12-11
Supplementary Methods from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
2025-12-11
Supplementary Figure 2 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
2025-12-11
Supplementary Materials from First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
2025-11-27
Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: Results of the glioblastoma expansion cohort
Neuro-Oncology Advances · 2025-11-19 · 2 citations
Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study
The Oncologist · 2025-10-01 · 2 citations
P3.12.21 Biomarker Analysis and Final Efficacy of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology · 2025-10-01
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer · 2025-08-01 · 3 citations
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts
Lung Cancer · 2025-07-15 · 2 citations
94P: Long-term efficacy of lorlatinib vs alectinib in patients with and without brain/central nervous system metastases: Matching-adjusted indirect comparisons
Journal of Thoracic Oncology · 2025-03-01 · 2 citations
IN-DEPTH CHARACTERIZATION OF THE SAFETY PROFILE OF BELZUTIFAN MONOTHERAPY IN PATIENTS WITH RENAL CELL CARCINOMA: A POOLED ANALYSIS OF FOUR CLINICAL TRIALS
Urologic Oncology Seminars and Original Investigations · 2025-02-27
Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
Journal of Clinical Oncology · 2025-02-10 · 5 citations
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study
Journal of Immunotherapy and Precision Oncology · 2025-01-14 · 2 citations
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
The Lancet Oncology · 2025-01-01 · 21 citations
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study
Future Oncology · 2024-11-08 · 1 citations
Supplementary Table S3 from Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma
2024-11-04